FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063622451> ?p ?o ?g. }

• W2063622451 endingPage "555" @default.
• W2063622451 startingPage "550" @default.
• W2063622451 abstract "Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) that has efficacy in recurrent malignant gliomas, particularly in combination with irinotecan. However, responses are rarely durable. Continuation of bevacizumab in combination with another chemotherapeutic agent may demonstrate some activity. In this article we present a retrospective review of 54 patients with recurrent malignant gliomas who progressed on a bevacizumab-containing regimen and were then treated with an alternate bevacizumab-containing regimen. All patients received intravenous bevacizumab (5–10 mg/kg) every 2 weeks alone or in combination with an additional chemotherapeutic agent, such as irinotecan. There was no limit on the number of prior therapies. Clinical characteristics and outcomes were reviewed. Tumor progression was determined by a combination of clinical status and radiographic changes. Patients were 33 men, 21 women (median age, 50 years; range, 23–72 years) with a median KPS score of 80 prior to the first bevacizumab-containing regimen and 70 prior to the second regimen; median prior chemotherapy regimens including the first bevacizumab-containing regimen was 3 (range, 2–5). Median progression-free survival (PFS) on the first bevacizumab-containing regimen was 124 days (95% confidence interval [CI], 87–154 days); 6-month (6M)-PFS was 33%. Median PFS on the second bevacizumab-containing regimen was 37.5 days (95% CI, 34–42 days); 6M-PFS was 2%. Ten patients on the first regimen and 12 patients on the second regimen suffered grade 3/4 toxicities. Those patients with malignant gliomas who progressed despite a bevacizumab-containing regimen rarely responded to the second bevacizumab-containing chemotherapeutic regimen. In such patients, alternate therapies should be considered." @default.
• W2063622451 created "2016-06-24" @default.
• W2063622451 creator A5001181010 @default.
• W2063622451 creator A5013091949 @default.
• W2063622451 creator A5021656597 @default.
• W2063622451 creator A5029013340 @default.
• W2063622451 creator A5063863193 @default.
• W2063622451 creator A5065591403 @default.
• W2063622451 creator A5074867738 @default.
• W2063622451 creator A5086484023 @default.
• W2063622451 creator A5091053515 @default.
• W2063622451 date "2009-10-01" @default.
• W2063622451 modified "2023-10-01" @default.
• W2063622451 title "Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab" @default.
• W2063622451 cites W1545570549 @default.
• W2063622451 cites W1858161324 @default.
• W2063622451 cites W1959628099 @default.
• W2063622451 cites W1977392502 @default.
• W2063622451 cites W1999574985 @default.
• W2063622451 cites W2002727873 @default.
• W2063622451 cites W2006202974 @default.
• W2063622451 cites W2018016372 @default.
• W2063622451 cites W2045115936 @default.
• W2063622451 cites W2093783077 @default.
• W2063622451 cites W2099808007 @default.
• W2063622451 cites W2125170899 @default.
• W2063622451 cites W2127745545 @default.
• W2063622451 cites W2150667715 @default.
• W2063622451 cites W2164761484 @default.
• W2063622451 cites W2264385870 @default.
• W2063622451 cites W2338264812 @default.
• W2063622451 cites W4233170666 @default.
• W2063622451 doi "https://doi.org/10.1215/15228517-2009-006" @default.
• W2063622451 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2765344" @default.
• W2063622451 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19332770" @default.
• W2063622451 hasPublicationYear "2009" @default.
• W2063622451 type Work @default.
• W2063622451 sameAs 2063622451 @default.
• W2063622451 citedByCount "155" @default.
• W2063622451 countsByYear W20636224512012 @default.
• W2063622451 countsByYear W20636224512013 @default.
• W2063622451 countsByYear W20636224512014 @default.
• W2063622451 countsByYear W20636224512015 @default.
• W2063622451 countsByYear W20636224512016 @default.
• W2063622451 countsByYear W20636224512017 @default.
• W2063622451 countsByYear W20636224512018 @default.
• W2063622451 countsByYear W20636224512019 @default.
• W2063622451 countsByYear W20636224512020 @default.
• W2063622451 countsByYear W20636224512021 @default.
• W2063622451 countsByYear W20636224512022 @default.
• W2063622451 countsByYear W20636224512023 @default.
• W2063622451 crossrefType "journal-article" @default.
• W2063622451 hasAuthorship W2063622451A5001181010 @default.
• W2063622451 hasAuthorship W2063622451A5013091949 @default.
• W2063622451 hasAuthorship W2063622451A5021656597 @default.
• W2063622451 hasAuthorship W2063622451A5029013340 @default.
• W2063622451 hasAuthorship W2063622451A5063863193 @default.
• W2063622451 hasAuthorship W2063622451A5065591403 @default.
• W2063622451 hasAuthorship W2063622451A5074867738 @default.
• W2063622451 hasAuthorship W2063622451A5086484023 @default.
• W2063622451 hasAuthorship W2063622451A5091053515 @default.
• W2063622451 hasBestOaLocation W20636224512 @default.
• W2063622451 hasConcept C121608353 @default.
• W2063622451 hasConcept C126322002 @default.
• W2063622451 hasConcept C141071460 @default.
• W2063622451 hasConcept C143998085 @default.
• W2063622451 hasConcept C2776694085 @default.
• W2063622451 hasConcept C2777802072 @default.
• W2063622451 hasConcept C2778227246 @default.
• W2063622451 hasConcept C2778336483 @default.
• W2063622451 hasConcept C2780259306 @default.
• W2063622451 hasConcept C2781413609 @default.
• W2063622451 hasConcept C502942594 @default.
• W2063622451 hasConcept C526805850 @default.
• W2063622451 hasConcept C71924100 @default.
• W2063622451 hasConceptScore W2063622451C121608353 @default.
• W2063622451 hasConceptScore W2063622451C126322002 @default.
• W2063622451 hasConceptScore W2063622451C141071460 @default.
• W2063622451 hasConceptScore W2063622451C143998085 @default.
• W2063622451 hasConceptScore W2063622451C2776694085 @default.
• W2063622451 hasConceptScore W2063622451C2777802072 @default.
• W2063622451 hasConceptScore W2063622451C2778227246 @default.
• W2063622451 hasConceptScore W2063622451C2778336483 @default.
• W2063622451 hasConceptScore W2063622451C2780259306 @default.
• W2063622451 hasConceptScore W2063622451C2781413609 @default.
• W2063622451 hasConceptScore W2063622451C502942594 @default.
• W2063622451 hasConceptScore W2063622451C526805850 @default.
• W2063622451 hasConceptScore W2063622451C71924100 @default.
• W2063622451 hasIssue "5" @default.
• W2063622451 hasLocation W20636224511 @default.
• W2063622451 hasLocation W20636224512 @default.
• W2063622451 hasLocation W20636224513 @default.
• W2063622451 hasLocation W20636224514 @default.
• W2063622451 hasOpenAccess W2063622451 @default.
• W2063622451 hasPrimaryLocation W20636224511 @default.
• W2063622451 hasRelatedWork W2052603427 @default.
• W2063622451 hasRelatedWork W2063622451 @default.
• W2063622451 hasRelatedWork W2101986864 @default.

• next